DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Terminated

Conditions: Testicular Germ Cell Tumor
Breast Cancer
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Neuroblastoma
Ovarian Cancer
Multiple Myeloma and Plasma Cell Neoplasm
Gestational Trophoblastic Tumor
Myelodysplastic Syndromes

Interventions: Other: flow cytometry
Other: laboratory biomarker analysis
Other: Data Collection

First Posted Date: 2008-04-03

Last Posted Date: 2019-11-15

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 150

Registration Number: NCT00651716

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Post-operative adjuvant therapy
Drug: neoadjuvant therapy
Procedure: therapeutic surgical procedure
Radiation: Radiation therapy with concurrent Paclitaxel
Drug: Hormonal Therapy

First Posted Date: 2008-03-31

Last Posted Date: 2017-02-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 38

Registration Number: NCT00647218

Locations: 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Cetner, Nashville, Tennessee, United States
🇺🇸
Methodist Lebonheur Healthcare, Memphis, Tennessee, United States

and more 3 locations

Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: irinotecan hydrochloride

First Posted Date: 2008-03-20

Last Posted Date: 2012-09-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 41

Registration Number: NCT00639769

Locations: 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸
VA Tennessee Valley Healthcare Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 5 locations

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: erlotinib hydrochloride
Genetic: TUNEL assay
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: liquid chromatography
Other: mass spectrometry
Other: matrix-assisted laser desorption ionization mass spectrometry
Procedure: therapeutic conventional surgery

First Posted Date: 2008-03-12

Last Posted Date: 2012-09-05

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00633750

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
Meharry Medical College, Nashville, Tennessee, United States

and more 2 locations

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: letrozole
Genetic: fluorescence in situ hybridization
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2008-02-11

Last Posted Date: 2012-08-09

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 48

Registration Number: NCT00611715

Locations: 🇺🇸
Jackson-Madison County Hospital, Jackson, Tennessee, United States
🇺🇸
The Jones Clinic - Germantown, Germantown, Tennessee, United States
🇺🇸
Tennessee Cancer Specialists, Knoxville, Tennessee, United States

and more 6 locations

Pain Control in Hospice Patients With Cancer-Related Pain

Completed

Conditions: Solid Tumor
Pain

Interventions: Other: medical chart review
Other: questionnaire administration
Other: survey administration

First Posted Date: 2008-02-07

Last Posted Date: 2012-10-24

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 22

Registration Number: NCT00609297

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Not Applicable

Terminated

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Radiation: total-body irradiation
Drug: methylprednisolone

First Posted Date: 2008-02-06

Last Posted Date: 2014-05-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT00608517

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

and more 1 locations

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

Not Applicable

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: celecoxib
Genetic: gene expression analysis
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: mass spectrometry
Procedure: biopsy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2008-02-06

Last Posted Date: 2013-03-05

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 10

Registration Number: NCT00608595

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Veterans Administration, Nashville, Tennessee, United States

A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Leukemia

First Posted Date: 2008-01-28

Last Posted Date: 2013-04-02

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT00601991

Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan

Terminated

Conditions: Mucositis
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Other: laboratory biomarker analysis

First Posted Date: 2008-01-28

Last Posted Date: 2013-03-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 95

Registration Number: NCT00602147

Locations: 🇺🇸
Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy